Supreme Court Blocks 5th Circuit Mifepristone Curbs, Preserving Telehealth Access for 2 in 3 Abortions
Updated
Updated · The Conversation · Jun 23
Supreme Court Blocks 5th Circuit Mifepristone Curbs, Preserving Telehealth Access for 2 in 3 Abortions
3 articles · Updated · The Conversation · Jun 23
Summary
A May 14 emergency order let providers resume prescribing mifepristone by telehealth, mail and pharmacies after the 5th Circuit briefly restored an in-person dispensing rule nationwide.
Louisiana’s October 2025 lawsuit against the FDA triggered the fight, arguing the agency’s 2023 removal of the in-person requirement was unlawful and harmed the state.
By late summer, the 5th Circuit is set to hear Louisiana’s appeal over a preliminary injunction, and whichever side loses is likely to seek Supreme Court review again.
A separate FDA “safety study” launched in early June could also reshape access, despite mifepristone’s 25-year record and criticism of the study used to justify renewed scrutiny.
Even if mifepristone restrictions return, misoprostol-only abortions would still be available, though they are slightly less effective—about 85% to 90% versus 95% with the two-drug regimen.
With mifepristone's safety under federal review, what are the medical alternatives for patients needing this common drug?
Could a 150-year-old law halt the mailing of modern, FDA-approved medications for abortion and miscarriage care?
As courts debate telehealth, what is the future for the 15,000 monthly abortions provided under state 'shield laws'?
Supreme Court Blocks Restrictions: The Future of Mifepristone and Medication Abortion for Two-Thirds of U.S. Patients
Overview
On May 14, 2026, the U.S. Supreme Court granted a temporary stay, blocking a lower court order that would have restricted access to the abortion pill mifepristone. This decision keeps current FDA regulations in place, allowing healthcare providers to prescribe mifepristone through telehealth and enabling patients to receive it by mail or at retail pharmacies. As a result, a crucial pathway for medication abortion remains open, even as the broader environment for abortion access in the U.S. remains fragmented and uncertain. The Supreme Court’s intervention provides temporary stability amid ongoing legal and political challenges.